注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
NextCure Inc是一家臨床階段的生物製藥公司,專注於發現和開發新型免疫藥物,通過恢復正常的免疫功能來治療癌症和其他免疫相關疾病。通過其專有的功能性,集成性,NextCure Discovery in Immuno-Oncology (FIND-IO) 平台,公司正在研究各種免疫細胞,以發現和了解免疫細胞的靶標和結構成分及其功能影響,以開發免疫藥物。其候選產品包括 NC318、NC410、NC762 和 NC 525。NC318是一種針對新型免疫調節蛋白Siglec-15的免疫藥物。NC410是一種新型免疫藥物,旨在阻斷由稱為白細胞相關免疫球蛋白樣受體的免疫調節劑介導的免疫抑制。NC762是一種針對稱為人B7同源物4蛋白的免疫調節分子的免疫藥物。NC525是一種新型LAIR-1抗體,選擇性靶向急性髓系白血病。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Michael S. Richman | 61 | 2015 | Co-Founder, CEO, President & Director |
Mario Sznol | 64 | - | Member of Scientific Advisory Board |
Stephen D. Miller | - | - | Member of Scientific Advisory Board |
Stephen W. Webster | 61 | 2019 | Independent Director |
David S. Kabakoff | 74 | 2015 | Independent Chairman of the Board |
Elaine V. Jones | 67 | 2015 | Independent Director |
Lieping Chen | 64 | 2015 | Co-Founder & Chairman of Scientific Advisory Board |
Chau Quang Khuong | 46 | 2015 | Independent Director |
John G. Houston | 63 | 2020 | Independent Director |
Anne Elizabeth Borgman-Hagey | 55 | 2021 | Independent Director |
Weiping Zou | - | 2021 | Member of Scientific Advisory Board |
Ellen Gwen Feigal | 69 | 2021 | Independent Director |
Brahm Segal | - | 2022 | Member of Scientific Advisory Board |
Lisa M. Coussens | - | 2022 | Member of Scientific Advisory Board |
Ursula A. Matulonis | - | 2021 | Member of Scientific Advisory Board |
Rakesh Dixit | - | 2024 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核